Lanean...
Community Clinical Practice Patterns and Mortality in Patients with Oncotype DX Intermediate Score: Who benefits from Chemotherapy?
BACKGROUND: Oncotype DX recurrence score (RS) is used as a tool for making decision about chemotherapy in hormone receptor-positive, HER2-negative breast cancer. There is no benefit of chemotherapy in node negative, RS 11–25, age ≥50 patients but the benefit of chemotherapy in the node positive grou...
Gorde:
| Argitaratua izan da: | Cancer |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6329644/ https://ncbi.nlm.nih.gov/pubmed/30387876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31818 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|